Open Actively Recruiting

A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis

About

Brief Summary

The purpose of this study is to provide an initial evaluation of the effectiveness of BMS-986278 in participants with lung fibrosis, to demonstrate the safety of BMS-986278, and provide information on the drug levels of BMS-986278 in these participants.

Primary Purpose
Treatment
Study Type
Interventional
Phase
Phase II

Eligibility

Gender
All
Healthy Volunteers
No
Minimum Age
21 Years
Maximum Age
N/A

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com.

Inclusion Criteria:

For the idiopathic pulmonary fibrosis (IPF) Cohort

  • Diagnosis of IPF within 7 years
  • Female and males ≥ 40 years of age For the progressive fibrotic interstitial lung disease (PF-ILD) Cohort
  • Evidence of progressive ILD within the 24 months before screening
  • Female and male ≥ 21 years of age.

Exclusion Criteria:

  • Women of childbearing potential (WOCBP)
  • Active Smokers
  • Patients with current malignancy
  • History of allergy to BMS-986278 or related compounds

Other protocol-defined inclusion/exclusion criteria apply

Join this Trial

Contact our clinical trial navigators for opportunities that may be suitable for you
Study Stats
Protocol No.
20-001707
Category
Pulmonary Disease
Principal Investigator
Contact
Eileen Callahan
Location
  • UCLA Westwood
For Providers
NCT No.
NCT04308681
For detailed technical eligibility, visit ClinicalTrials.gov.